ViroPharma is Proud to be a Friend of Rare Disease Day 2013!

         ViroPharma is Proud to be a Friend of Rare Disease Day 2013!

  PR Newswire

  MAIDENHEAD, England, February 28, 2013

MAIDENHEAD, England, February 28, 2013 /PRNewswire/ --

   --Rare Disease Day takes place on 28 February 2013 and this year's theme
                focuses on 'Rare Disorders without Borders'--

   --ViroPharma Incorporated is an international biopharmaceutical company
 committed to supporting patients with serious diseases for which there is an
                             unmet medical need--

ViroPharma Incorporated (NASDAQ: VPHM), an international biopharmaceutical
company committed to supporting patients with serious diseases for which there
is an unmet medical need, today announced its participation in the sixth
international Rare Disease Day. Rare Disease Day is coordinated by the
European Organisation for Rare Diseases (EURORDIS) and by the National
Organization for Rare Disorders (NORD) in the US and encourages patient
organisations from across the globe to organise awareness-raising activities
around this year's theme ' Rare Disorders without Borders'.

This year's theme focuses on helping to drive cross-border cooperation for
diseases which affect only a few people in each country and for which
expertise is scarce and scattered. There are more than 6,000 rare diseases
affecting more than 60 million people in Europe and the US alone. ^[1] Most of
these diseases are genetic, serious, chronic and debilitating, and 50 percent
of rare diseases touch children. ^[ ^1 ^]

"ViroPharma is a proud member of EURORDIS and is delighted to be participating
in this year's Rare Disease Day. At ViroPharma, we are committed to improving
the lives of patients and believe in the value of this year's theme to create
a network of solidarity for patients living with these diseases," said Thierry
Darcis, Vice President, General Manager, ViroPharma, Europe. "We understand
the isolation felt by many people living with rare diseases, and will continue
to deliver solutions that address critical gaps in care for patients living
with few, if any, clinical treatment options."

ViroPharma provides novel treatment solutions for patients living with rare
diseases including hereditary angioedema, adrenal insufficiency, prolonged,
acute, convulsive seizures, and Clostridium difficile infection.

As part of its commitment to improving the lives of patients with rare
diseases in Europe, ViroPharma sponsors and funds educational initiatives
including:

  *The Hereditary Angioedema Burden of Illness Study in Europe
    (HAE-BOIS-Europe), an innovative, patient-centric, multi-country study of
    the humanistic and economic burden of HAE to address and improve current
    knowledge gaps surrounding the condition.
  *The PERFECTâ„¢ (Practices in Emergency and Rescue medication For Epilepsy
    managed with Community administered Therapy) Initiative, which aims to
    document and communicate first of its kind data on the impact of conflict
    of policy, guidelines and actual practice in the care of prolonged, acute,
    convulsive seizures in infants, toddlers, children and adolescents in the
    non-hospital setting.

ViroPharma Incorporated is based in Exton, Pennsylvania, US, and also has
offices in Canada and in eight European countries including Belgium, France,
Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom. ViroPharma
is continuing to grow its footprint and presence in Europe, and to support
this growth set up its first European subsidiary in 2007, leveraging in Europe
the company's expertise in the development and commercialisation of
biotechnology products, and in business development.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements
that involve a number of risks and uncertainties. Forward-looking statements
provide our current expectations or forecasts of future events, including our
ability to continue to deliver solutions that address critical gaps in care
for patients living with few, if any, clinical treatment options. There can be
no assurance that we will be successful in our efforts to continue to deliver
solutions in the future. These factors, and other factors, including, but not
limited to those described in our annual report on Form 10-K for the year
ended December 31, 2012 and quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission for the periods ended March 31, 2012, June
30, 2012 and September 30, 2012, could cause future results to differ
materially from the expectations expressed in this press release. The
forward-looking statements contained in this press release are made as of the
date hereof and may become outdated over time. ViroPharma does not assume any
responsibility for updating any forward-looking statements. These
forward-looking statements should not be relied upon as representing our
assessments as of any date subsequent to the date of this press release.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercialising novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few, if any, clinical therapeutic options, including C1 esterase
inhibitor deficiency, treatment of seizures in children and adolescents,
adrenal insufficiency, and C. difficile infection (CDI). Our goal is to
provide rewarding careers to employees, to create new standards of care in the
way serious diseases are treated, and to build international partnerships with
the patients, advocates, and healthcare professionals we serve.

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's website, http://www.viropharma.com/ . The company encourages
investors to consult these sections for more information on ViroPharma and our
business.

References

1. Rare Disorders without Borders. Available at:
http://www.rarediseaseday.org/article/rare-disorders-solidarity-has-no-border
. Last accessed January 2013.

Contact: VIROPHARMA INCORPORATED Contacts: Thierry Darcis, Vice President,
General Manager, ViroPharma, Europe, Phone: +44-(0)20-7572-1222; Emma White
(Media Enquiries), PR, Advocacy & Communications Manager, Phone:
+44-(01)628-582732
 
Press spacebar to pause and continue. Press esc to stop.